Utility of Squamous Cell Carcinoma Antigen (SCCA) in Psoriasis
NCT ID: NCT04308616
Last Updated: 2022-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
51 participants
OBSERVATIONAL
2020-07-20
2022-04-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation) but they suffer from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time.
A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.
NCT02752776
Cytokine Expression in Psoriasis Patients with and Without Joint Involvement
NCT05307809
Immunologic Response to Secukinumab in Plaque Psoriasis
NCT02592018
Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
NCT04722640
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
NCT04316585
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Clinical scores of psoriasis severity are used in consultation to guide treatment of the disease (initiation of systemic therapy, dose escalation). The PASI (Psoriasis Assessment Severity Index, minimum score 0, maximum 72) is the most widely used. It suffers from several pitfalls: lack of inter- and intra-observer reproducibility, consumption of medical time. This PASI score was "unavoidable" in the international clinical studies used to obtain marketing authorisation for medicines. The PGA (Physician global assessment) is simpler and less time-consuming, ranging from 0 to 4, but is not very discriminating. More recently, a "Simplified Psoriasis Index" (proSPI) health professional score has been developed, which correlates well with PASI for the severity component of psoriasis and with quality of life for the psychological component of the disease. It is less time-consuming to establish than PASI, but suffers like all clinical scores from a problem of inter- and intra-observer reproducibility.
A readily available, inexpensive (24 euros) blood marker could be an interesting alternative to these clinical scores.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Psoriasis
Patients with psoriasis
Blood samples
Blood samples
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples
Blood samples
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with skin psoriasis (new and untreated or being treated, flare-up or stable, possibly bleached)
* Requiring a blood sample for disease or treatment monitoring
Exclusion Criteria
* Patient under guardianship or curatorship
* Opposition to participation in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Laurent MACHET, MD-PhD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Tours
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dermatology Service, University Hospital, Tours
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-A00105-34
Identifier Type: OTHER
Identifier Source: secondary_id
RIPH3-RNI19/SCCAPSO
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.